Interesting that the 1b breast cancer results are now extended from May to early 2H (investor presentation Ann.).
That is, the cohert of patients is now wider in parameters incorporating those of an even less quality of life than the cohort of the 1A trial.
That said, inferentially, one can only assume that early data has spured on the decision to extend the cohort and, alas, the timeframe.
IMO, and that's why ptx is on the rise.
GLTAH
Interesting that the 1b breast cancer results are now extended...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
